STEMON Inc., established in 2018, specializes in cell reprogramming technologies, particularly in autologous cell therapy. Utilizing their proprietary Entr® technology, they produce customized exosomes for therapeutic and cosmetic applications. STEMON focuses on the mass production of Reprosome®, offering innovative solutions in healthcare, targeting conditions like immune and respiratory diseases. The company also develops skincare and haircare products, leveraging their expertise in cell therapy and exosome technology to grow globally.